TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type Lung Cancer
This study is:

* A multicenter, prospective, randomized, phase 3 trial.
* To prove non-inferiority of Taxotere/Cisplatin compared to Pemetrexed/Cisplatin as a front line treatment of patients with non-squamous cell lung cancer.
* 276 patients will be recruited.
Carcinoma, Non Small Cell Lung
DRUG: Taxotere|DRUG: Pemetrexed
Progression Free Survival, months after beginning of first cycle chemotherapy, one year
Overall Survival (months from the beginning of first cycle chemotherapy), months from the beginning of first cycle chemotherapy, three years|Safety Profile, Toxicity using CTCAE version 4.0, four months|Response rate, Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, 6-7th week
Docetaxel is being used in 60mg/m2 3 weekly dosage in Japan and several east Asian institutions. Docetaxel 60mg/m2 and Cisplatin 70 mg/m3 3 weekly regimen will be compared to Pemetrexed 500mg/m2 and Cisplatin 70 mg/m2 3 weekly regimen in first line NSCLC with non-squamous histology.